TRBC1 and leukemia: They engineered third-generation (CD28 and OX40 costimulatory domains) anti-TRBC1 CAR T cells that were proved to recognized and killed normal and malignant TRBC1+ but not TRBC2+ T cells in vitro, and in a disseminated mouse model of leukemia.